» Articles » PMID: 22677237

Catheter-based Renal Denervation for Treatment of Resistant Hypertension

Overview
Journal Dan Med J
Specialty General Medicine
Date 2012 Jun 9
PMID 22677237
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Activation of renal sympathetic nerves is associated with the development of hypertension. Catheter-based renal sympathetic denervation with radiofrequency energy ablation is a new promising treatment option for resistant hypertension. We here report the first Danish experiences and results with this technique.

Material And Methods: Nine patients with resistant hypertension and a day-time 24-hour ambulatory blood pressure (BP) of 152/89 mmHg ± 10/10 (standard deviation) mmHg despite treatment with 5.4 ± 1.4 anti-hypertensive drugs underwent catheter-based renal sympathetic denervation with the Symplicity catheter.

Results: No periprocedural complications or adverse events during follow-up were observed. Seven patients received complete ablation and two patients only partial ablation. Five patients responded to the treatment with a reduction in day-time 24-hour ambulatory BP from 158/94 ± 13/9 mmHg to 139/82 ± 10/8 mmHg (p < 0.05) at the one month follow-up and a reduction in the number of anti-hypertensive drugs from 5.4 ± 1.6 to 3.4 ± 0.9 (p < 0.05). BP in the remaining four patients was not significantly changed and antihypertensive therapy was not changed.

Conclusion: Catheter-based renal sympathetic denervation is a feasible and in several cases also effective treatment option for patients with resistant hypertension. Adequately designed controlled trials are needed to assess the long-term safety and the full potential of this treatment.

Citing Articles

Renal Denervation Promotes Atherosclerosis in Hypertensive Apolipoprotein E-Deficient Mice Infused with Angiotensin II.

Wang Y, Dinh T, Nield A, Krishna S, Denton K, Golledge J Front Physiol. 2017; 8:215.

PMID: 28450836 PMC: 5390019. DOI: 10.3389/fphys.2017.00215.


One year follow-up effect of renal sympathetic denervation in patients with resistant hypertension.

Pourmoghaddas M, Khosravi A, Akhbari M, Akbari M, Pourbehi M, Ziaei F ARYA Atheroscler. 2016; 12(2):109-13.

PMID: 27429632 PMC: 4933751.


Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial.

Mathiassen O, Vase H, Bech J, Christensen K, Buus N, Schroeder A J Hypertens. 2016; 34(8):1639-47.

PMID: 27228432 PMC: 4933576. DOI: 10.1097/HJH.0000000000000977.


Renal denervation for the management of resistant hypertension.

Patel H, Hayward C, Vassiliou V, Patel K, Howard J, Di Mario C Integr Blood Press Control. 2015; 8:57-69.

PMID: 26672761 PMC: 4675644. DOI: 10.2147/IBPC.S65632.


Ethnicity and sympathetic tone: predictors of the blood pressure response to renal denervation?.

Wang Y Nat Rev Cardiol. 2014; 11(11):638.

PMID: 25267424 DOI: 10.1038/nrcardio.2014.70-c1.